USPTO serial 86034320
TPU PHARMA
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- WIENER, MICHAEL
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with TPU PHARMA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Bret E. Field
BRET E. FIELD Bozicevic, Field & Francis LLP201 Redwood Shores Parkway, Suite 200Redwood City, CA 94065UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Cosmetics; cosmetic preparations; adhesives for cosmetic purposes; cosmetic masks; soaps for personal use; perfumery; essential oils; hair lotions | ACTIVE | — |
| 005 | Pharmaceuticals for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; pharmaceutical preparations, compositions, creams and lotions for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; prescription and over-the-counter pharmaceutical preparations for the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; prescription and over-the-counter pharmaceutical preparations, namely, transdermal gel formulations, transdermal cream formulations, oral mucous formulations, transdermal patches, dressings and medical adhesive tapes for use in the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions; pharmaceutical products, namely, analgesics | ACTIVE | — |
| 042 | Pharmaceutical research and development; pharmaceutical product evaluation, testing and inspection services; providing medical and scientific research information in the field of pharmaceuticals; information, advisory and consultancy services relating to all the aforesaid services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Teikoku Pharma USA, Inc.
- Other trademarks owned by Teikoku Pharma USA, Inc.
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named TPU PHARMA
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 10, 2017 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 10, 2017 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jan 9, 2017 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 8, 2016 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 7, 2016 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Sep 2, 2016 | EXT5 | SOU EXTENSION 5 FILED | — |
| Sep 2, 2016 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 8, 2016 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 7, 2016 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Feb 29, 2016 | EXT4 | SOU EXTENSION 4 FILED | — |
| Feb 29, 2016 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 29, 2016 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 20, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 19, 2015 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Aug 13, 2015 | EXT3 | SOU EXTENSION 3 FILED | — |
| Aug 13, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 10, 2015 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 9, 2015 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Apr 2, 2015 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Feb 26, 2015 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 26, 2015 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 16, 2014 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 14, 2014 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 14, 2014 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 14, 2014 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 8, 2014 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 4, 2014 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 7, 2014 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 7, 2014 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 18, 2013 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 3, 2013 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Nov 26, 2013 | ALIE | ASSIGNED TO LIE | — |
| Nov 25, 2013 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 25, 2013 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 25, 2013 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 25, 2013 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 25, 2013 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 23, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 21, 2013 | MPMK | NOTICE OF PSEUDO MARK E-MAILED | — |
| Aug 20, 2013 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 13, 2013 | NWAP | NEW APPLICATION ENTERED | — |